Alison Hannah, Lynn Tetrault
NeoGenomics announced the election of Alison Hannah and Lynn Tetrault to its board. Hannah has more than 25 years of experience in developing investigational cancer chemotherapies and has been a consultant to the pharma industry since 2000. She previously was senior medical director at Sugen. She will serve on NeoGenomics' compliance committee.
Tetrault is a consultant to healthcare companies and is a director of Women's Way. She was at AstraZeneca between 1993 and 2014 and was most recently its executive vice president of HR and corporate affairs. She will chair NeoGenomics' nominating and governance committee and will be a member of the compensation committee.